Phase 2 Trial of ALK-001 in Stargardt Disease and Treatment Indications for Dry AMD/GA

Time: 11:15 am
day: Day Two


  • ALK-001 is a first in class inhibitor of vitamin A dimerization
  • Results of a randomized, placebo-controlled, clinical trial indicates that
  • ALK-001 has disease modifying ability on the progression of Stargardt Disease
  • ALK-001 is also being tested in Geographic Atrophy associated with dry-AMD in a fully enrolled Phase 3 study.